Neurohypophyseal Diabetes Insipidus
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Neurohypophyseal Diabetes Insipidus

What is the definition of Neurohypophyseal Diabetes Insipidus?

Arginine vasopressin deficiency (previously called neurohypophyseal diabetes insipidus) is a disorder of water balance. The body normally balances fluid intake by releasing fluid in urine. However, people with arginine vasopressin deficiency produce an excessive amount of urine (polyuria), which depletes the amount of water in the body. This water loss also leads to excessive thirst (polydipsia).

What are the causes of Neurohypophyseal Diabetes Insipidus?

The familial form of arginine vasopressin deficiency is caused by variants (also called mutations) in the AVP gene. This gene provides instructions for making a hormone called arginine vasopressin (AVP), which is sometimes also called antidiuretic hormone (ADH). This hormone, which is produced and stored in the brain, helps control the body's water balance.

How prevalent is Neurohypophyseal Diabetes Insipidus?

Arginine vasopressin deficiency occurs in approximately 1 in 25,000 individuals. The acquired form is much more common than the familial form.

Is Neurohypophyseal Diabetes Insipidus an inherited disorder?

Familial arginine vasopressin deficiency is almost always inherited in an autosomal dominant pattern, which means that one copy of the altered AVP gene in each cell is sufficient to cause the disorder.

Who are the top Neurohypophyseal Diabetes Insipidus Local Doctors?
Ilan Gabriely
Distinguished in Neurohypophyseal Diabetes Insipidus
Endocrinology | Internal Medicine
Distinguished in Neurohypophyseal Diabetes Insipidus
Endocrinology | Internal Medicine

Reading Hospital Endocrinology & Diabetes Center Wyomissing

1001 Reed Ave, Ste 402, 
Wyomissing, PA 
Languages Spoken:
English

. Dr. Gabriely is rated as a Distinguished provider by MediFind in the treatment of Neurohypophyseal Diabetes Insipidus. His top areas of expertise are Low Blood Sugar, Hyperparathyroidism, Thyroid Cancer, and Anaplastic Thyroid Cancer.

Elite in Neurohypophyseal Diabetes Insipidus
Elite in Neurohypophyseal Diabetes Insipidus
Basel, BS, CH 

Mirjam Crain-Christ practices in Basel, Switzerland. Crain-Christ is rated as an Elite expert by MediFind in the treatment of Neurohypophyseal Diabetes Insipidus. Their top areas of expertise are Diabetes Insipidus (DI), Neurohypophyseal Diabetes Insipidus, Low Sodium Level, Osmotic Diuresis, and Hormone Replacement Therapy (HRT).

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Neurohypophyseal Diabetes Insipidus
Elite in Neurohypophyseal Diabetes Insipidus
Basel, BS, CH 

Cihan Atila practices in Basel, Switzerland. Atila is rated as an Elite expert by MediFind in the treatment of Neurohypophyseal Diabetes Insipidus. Their top areas of expertise are Neurohypophyseal Diabetes Insipidus, Diabetes Insipidus (DI), Low Sodium Level, and Osmotic Diuresis.

What are the latest Neurohypophyseal Diabetes Insipidus Clinical Trials?
Oxytocin Substitution Therapy in Patients With AVP Deficiency (Central Diabetes Insipidus)

Summary: This randomized, placebo-controlled, double-blind trial aims to investigate intranasal OXT as a novel therapeutical option in central diabetes insipidus (cDI) to improve psychological symptoms and socio-emotional functioning. Optionally, patients can present for additional assessments in sub-studies: * fMRI sub-study at day 14 (± 2 days) (one additional visit) * Social-stress sub-study at day 14 (...

Match to trials
Find the right clinical trials for you in under a minute
Get started
The OxyPLEASURE Study - Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency (Central Diabetes Insipidus) and Healthy Controls - a Double-blind Randomized Placebo-controlled Crossover Trial

Summary: The study aims to investigate whether intranasal oxytocin (OXT) improves sexual well-being in patients with Arginine Vasopressin Deficiency (AVP-D). The trial consists of two parts: Part A assesses the effect of OXT on sexual well-being and intimacy over a 7-day treatment period in participants in a stable partnership. Part B assesses the effect of a single dose OXT on sexual arousal, fear and emp...

Who are the sources who wrote this article ?

Published Date: July 19, 2024
Published By: National Institutes of Health